Breaking News

Sigma-Tau Names CEO

April 29, 2013

Lemus takes on newly created position

Dave Lemus has been promoted to the newly created position of chief executive officer of Sigma-Tau Pharmaceuticals. Mr. Lemus has served as chief operating officer since March 2012, and joined the company as vice president of finance in July 2011.
 
Prior to joining the company, Mr. Lemus was executive vice president and chief financial officer of MorphoSys AG, where he launched Germany's first biotech IPO in 1999. Before MorphoSys, Mr. Lemus held a variety of senior management positions at Hoffmann-La Roche and Lindt Chocolate, in Switzerland. Mr. Lemus presently serves as board chairman of Proteros Gmbh in Munich, and as a non-executive board member of Axela Inc. in Toronto.
 
Professor Trevor M. Jones CBE, president of Sigma Tau USA Inc., said, "We are delighted to appoint Dave to this new position. His appointment comes at a pivotal time in the development of the company, as it now expands via commercialization of its proprietary internal R&D pipeline, and the pursuit of externally driven growth opportunities. The appointment of the chief executive role reflects the commitment Sigma Tau USA Inc. has to the field of rare diseases, and to the significant impact we expect these medicines will ultimately have on their respective physician and patient communities, alike."
 

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important